ReviewAsian journal of urology2025
The impact of deferred cytoreductive nephrectomy on survival in advanced renal cell carcinoma: A systematic review and meta-analysis.
Review in Asian journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Stage IV renal cell carcinoma (RCC) is associated with a significant decrease in survival rates. Cytoreductive nephrectomy (CN) is one of the treatments for stage IV RCC. However, there are studies showing that delayed CN might have benefits for the survival of the patients. We aimed to examine the impact of deferred CN on the survival of patients with advanced RCC in relation to sequential management with targeted therapy (TT). Methods: A literature search was conducted in PubMed, EMBASE, EBSCOhost, MedRxiv, and Scopus. We included the randomized clinical trial and non-randomized study of intervention comparing the overall survival (OS) of upfront CN with deferred CN in patients with advanced RCC undergoing TT. Meta-analysis was carried out using Review Manager v5.4 software. The fixed-effect and random-effects models were used to obtain pooled estimates using the hazard ratio and standard error, presented using the forest plot with 95% confidence interval. Results: Four studies were analyzed quantitatively. Our analysis revealed that patients with upfront TT followed by deferred CN had significantly improved OS compared to those who underwent upfront CN followed by TT (hazard ratio 0.50, 95% confidence interval 0.40-0.64, Conclusion: The findings of the study suggest that considering upfront TT followed by deferred CN may lead to improved OS in patients with advanced RCC. However, more research is needed to fully understand the role, optimal timing, and sequencing of TT and CN in the treatment of advanced RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.